Seres Therapeutics, Inc. (MCRB): Price and Financial Metrics

Seres Therapeutics, Inc. (MCRB): $0.65

0.03 (-4.03%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add MCRB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#107 of 360

in industry

MCRB Price/Volume Stats

Current price $0.65 52-week high $6.87
Prev. close $0.68 52-week low $0.63
Day low $0.63 Volume 4,133,500
Day high $0.70 Avg. volume 4,625,907
50-day MA $0.93 Dividend yield N/A
200-day MA $2.05 Market Cap 98.87M

MCRB Stock Price Chart Interactive Chart >


Seres Therapeutics, Inc. (MCRB) Company Bio


Seres Therapeutics is a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company was founded in 2010 and is based in Cambridge, Massachusetts.


MCRB Latest News Stream


Event/Time News Detail
Loading, please wait...

MCRB Latest Social Stream


Loading social stream, please wait...

View Full MCRB Social Stream

Latest MCRB News From Around the Web

Below are the latest news stories about SERES THERAPEUTICS INC that investors may wish to consider to help them evaluate MCRB as an investment opportunity.

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

CAMBRIDGE, Mass., December 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteri

Yahoo | December 8, 2023

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%

Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to...

Yahoo | December 2, 2023

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

CAMBRIDGE, Mass., November 28, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.

Yahoo | November 28, 2023

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo

Yahoo | November 21, 2023

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kevin Mannix, Head of Investor Relations. Please go ahead. Kevin Mannix: […]

Yahoo | November 5, 2023

Read More 'MCRB' Stories Here

MCRB Price Returns

1-mo -17.27%
3-mo N/A
6-mo -55.17%
1-year -88.91%
3-year -96.96%
5-year -90.67%
YTD -53.57%
2023 -75.00%
2022 -32.77%
2021 -66.00%
2020 610.14%
2019 -23.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!